Mixed connective tissue disease

Mixed connective tissue disease (MCTD) is a systemic autoimmune overlap syndrome characterised by the combination of features from systemic lupus erythematosus (SLE), systemic sclerosis (SSc), polymyositis/dermatomyositis, and rheumatoid arthritis — occurring in association with high-titre anti-U1 ribonucleoprotein (anti-U1 RNP) antibodies. First described by Sharp et al. in 1972, MCTD was initially considered a distinct entity with a favourable prognosis, but longitudinal studies show it has significant morbidity, particularly from pulmonary arterial hypertension (PAH), which is the leading cause of mortality. MCTD predominantly affects women in the second to fourth decade (female:male ~9:1). The hallmark clinical features are Raynaud phenomenon, swollen (puffy) fingers, inflammatory arthritis, inflammatory myopathy, and oesophageal dysmotility.

The pathogenesis of MCTD centres on immune dysregulation driven by anti-U1 RNP antibodies and T cell-mediated autoimmunity, producing vasculopathy and end-organ inflammation across multiple systems.

Key Pathogenic Mechanisms

• Anti-U1 RNP antibodies — directed against the U1 small nuclear ribonucleoprotein (snRNP) complex; pathogenic via immune complex deposition, complement activation, and TLR-mediated innate immune activation; anti-U1 70kD subunit correlates with myositis and PAH
• Vasculopathy — intimal proliferation and medial hypertrophy in small vessels; PAH is the most severe vasculopathic manifestation; Raynaud phenomenon reflects vasospasm; endothelial apoptosis and growth factor dysregulation drive vascular remodelling
• T cell dysregulation — Th1/Th2/Th17 imbalance; CD4+ T cell infiltration in muscle (myositis) and synovium (arthritis); cytokines (IL-6, TNF-α, IFN-γ, TGF-β) drive organ-specific inflammation and fibrosis
• Fibrosis — TGF-β-driven; contributes to oesophageal dysmotility, ILD, and skin thickening (less severe than SSc)
• Genetic predisposition — HLA-DR4 and HLA-DRw53 associations; shared genetic risk with SLE and SSc

MCTD presents insidiously with Raynaud phenomenon as the most common initial feature, followed by progressive development of overlap features. The classic triad of Raynaud phenomenon, swollen fingers, and high-titre anti-U1 RNP should prompt consideration of MCTD.

The diagnostic cornerstone of MCTD is a high-titre anti-U1 RNP antibody. Comprehensive baseline organ assessment is required given the multi-system nature of the disease, with particular attention to PAH and ILD screening.

• Essential
  Anti-U1 RNP antibody (high titre)

  Defining antibody of MCTD — typically very high titre (>1:1600 by immunofluorescence or strongly positive by ELISA/line blot). Anti-U1 RNP is part of the anti-ENA panel. Positive ANA (speckled pattern) almost universal. Anti-Sm, anti-dsDNA, anti-Ro/SSA and anti-La/SSB may coexist but at lower titres.
• Essential
  Full ANA panel (anti-Sm, anti-dsDNA, anti-Ro, anti-La, anti-Scl-70, anti-centromere)

  To characterise overlap features and exclude predominant SLE or SSc. Anti-Sm suggests SLE component; anti-Scl-70 or anti-centromere suggest SSc-dominant disease. Anti-dsDNA is typically low or absent in pure MCTD.
• Essential
  FBC, UEC, LFTs, ESR, CRP, CK, aldolase

  Lymphopenia common; leucopenia; elevated CK indicates myositis (may be markedly elevated); LDH and aldolase are sensitive myositis markers. ESR elevated; CRP less so unless serositis present.
• Essential
  Echocardiogram — baseline and annual PAH screening

  PAH affects 15–25% of MCTD patients and is the leading cause of mortality. Estimated RVSP >40 mmHg requires formal right heart catheterisation. Annual echo is mandatory for all MCTD patients. NT-proBNP as adjunct PAH screening marker.
• Essential
  PFTs (FVC + DLCO) — baseline and annual

  ILD surveillance and PAH screening. Declining DLCO with preserved FVC pattern suggests PAH; declining FVC and DLCO suggests ILD. 6-monthly if ILD present or declining.
• Recommended
  HRCT chest

  Baseline in all patients; NSIP most common ILD pattern in MCTD. Repeat if FVC declines or respiratory symptoms develop. Pulmonology co-management if ILD present.
• Recommended
  Urinalysis, urine protein:creatinine ratio

  Renal involvement is less severe than in SLE but monitoring is required. Proteinuria and haematuria prompt renal biopsy to guide therapy.
• Recommended
  Complement C3, C4 and urinalysis

  Low complement may indicate SLE overlap with active nephritis; low C4 with cryoglobulinaemia indicates vasculitis. Monitor when SLE-like features present.
• Recommended
  MRI muscles / muscle biopsy

  Indicated when myositis is clinically suspected (weakness, elevated CK) — MRI identifies active muscle inflammation for biopsy targeting. Biopsy confirms myositis subtype. EMG and nerve conduction studies for neuropathy assessment.

MCTD risk stratification focuses on identifying organ-threatening disease, particularly PAH and significant ILD, which drive mortality. Disease activity is monitored across multiple organ domains.

Treatment in MCTD is organ-based and driven by the predominant component disease at any given time. Hydroxychloroquine is the anchor therapy. Corticosteroids and immunosuppression are used for inflammatory flares; PAH and ILD require targeted intervention.

Directed therapy in MCTD addresses specific dominant manifestations requiring targeted management.

Pulmonary Arterial Hypertension

• Confirm PAH by right heart catheterisation — mPAP >20 mmHg with PVR >2 Wood units at rest; do not treat based on echo RVSP estimate alone
• WHO functional class II: ERA monotherapy (bosentan PBS-listed for PAH) or sildenafil (PBS-listed for PAH)
• WHO functional class III–IV: combination therapy ERA + PDE5 inhibitor; consider riociguat (not with PDE5 inhibitor); iloprost or epoprostenol IV for refractory disease
• Referral to specialist PAH centre — combined immunosuppression and PAH therapy may be beneficial in MCTD-PAH given inflammatory aetiology; rituximab or cyclophosphamide in refractory MCTD-PAH

Inflammatory Myositis

• Prednisolone 1 mg/kg/day — first-line for active myositis; taper guided by CK normalisation and clinical response
• Steroid-sparing: methotrexate 15–25 mg/week, azathioprine 2–3 mg/kg/day, or MMF 2–3 g/day
• Refractory myositis — IVIg 2 g/kg over 2–5 days; rituximab (anti-CD20) for refractory inflammatory myopathy; tacrolimus for refractory cases with ILD
• Physiotherapy and exercise rehabilitation — graded exercise programme once disease is controlled; avoid exercise during active myositis (may worsen)

Raynaud Phenomenon and Digital Ischaemia

• Nifedipine modified release 20–40 mg twice daily — first-line (PBS-listed for Raynaud in CTD)
• Sildenafil for refractory Raynaud or digital ulcers not responding to CCB
• Bosentan for prevention of new digital ulcers (PBS-listed for SSc digital ulcer prevention — may apply in MCTD)
• Avoid beta-blockers, vasoconstrictors, and smoking — all worsen Raynaud vasospasm

Arthritis

• NSAIDs — for mild arthralgia; short-term use; avoid in renal impairment
• HCQ + low-dose prednisolone for mild-moderate inflammatory arthritis
• Methotrexate — first-line DMARD for persistent or erosive arthritis
• Biologics — TNF inhibitors (e.g., etanercept, adalimumab) for methotrexate-refractory arthritis; use with caution given SLE-like features (may worsen SLE component)

Non-pharmacological management is integral to MCTD care, addressing functional limitations, Raynaud protection, fatigue, and nutritional support.

Raynaud and Vascular Protection

• Thermal protection — heated gloves, hand warmers, layered clothing; avoid cold environments and cold water immersion
• Smoking cessation — mandatory; tobacco dramatically worsens vasospasm and digital ischaemia
• Avoid vasoconstrictors — beta-blockers, sympathomimetics, nasal decongestants; review all medications

Physiotherapy and Rehabilitation

• Myositis rehabilitation — graded aerobic exercise when myositis controlled; resistance training to rebuild muscle mass; supervised programme initially
• Hand exercises — range-of-motion for puffy or sclerodactylous fingers; occupational therapy for adaptive devices
• Respiratory physiotherapy — breathing exercises for ILD; pulmonary rehabilitation programme

Nutritional and GI Support

• High-dose PPI — omeprazole 40 mg twice daily for GERD; prokinetics for dysmotility
• Hand exercises — range-of-motion for puffy or sclerodactylous fingers; occupational therapy for adaptive devices
• Respiratory physiotherapy — breathing exercises for ILD; pulmonary rehabilitation programme

Nutritional and GI Support

• High-dose PPI — omeprazole 40 mg twice daily for GERD; prokinetics for dysmotility
• Dietitian referral — for dysphagia-related malnutrition or myositis-related nutritional deficits

Psychological Support

• Fatigue, pain, and functional limitation have significant psychological burden — psychology referral for depression and adjustment difficulties
• Arthritis Australia and Scleroderma Australia — patient support resources

MCTD requires structured lifelong monitoring across multiple organ domains, with PAH surveillance being the highest priority.

When to Refer Urgently

• Cardiology/Pulmonology: Echo RVSP >40 mmHg, progressive dyspnoea, elevated NT-proBNP — urgent RHC for PAH diagnosis
• Neurology: Progressive trigeminal neuropathy, mononeuritis multiplex, CNS manifestations
• Nephrology: Proteinuria >1 g/day, rising creatinine, active urinary sediment

MCTD requires specific considerations in certain patient groups.

MCTD in Pregnancy

• Anti-U1 RNP — transplacental passage; neonatal lupus and congenital heart block risk (lower than anti-Ro/SSA but present); fetal echocardiography surveillance 16–26 weeks
• Hydroxychloroquine — continue throughout pregnancy; reduces neonatal lupus risk; safe in breastfeeding
• PAH in MCTD is a contraindication to pregnancy — maternal mortality risk >25%
• Teratogenic drugs — MMF, MTX, bosentan must be stopped ≥3 months pre-conception; azathioprine is preferred steroid-sparing agent in pregnancy
• SLE component flares — increased risk in second/third trimester; monitor complement, anti-dsDNA, urinalysis

MCTD vs Undifferentiated CTD (UCTD)

• UCTD — ANA-positive CTD with features not meeting criteria for any specific diagnosis; may evolve into MCTD, SLE, SSc, or remain undifferentiated
• Key differentiator — high-titre anti-U1 RNP is the defining serological feature of MCTD; absence of this antibody despite overlap features = UCTD or other overlap
• Annual monitoring for evolution — repeat ANA panel annually in UCTD; organ screening for PAH and ILD

Disease Evolution Over Time

• MCTD may evolve towards one dominant component disease (SSc, SLE, or PM/DM) over 10–15 years in some patients
• Anti-U1 RNP titres may decline with disease duration; persistent high titres correlate with ongoing PAH risk
• Long-term follow-up required — regular reassessment of antibody profile and organ involvement

Stewardship in MCTD focuses on appropriate PAH diagnosis before treatment, avoiding teratogenic drugs without contraception, and vigilant monitoring for treatment toxicity.

GP Role in MCTD Management

• Annual PAH screening coordination — ensure echocardiogram is arranged annually and results communicated to rheumatologist
• Raynaud management — prescribe nifedipine modified release; educate on thermal protection; avoid vasoconstrictors
• Immunosuppression monitoring — FBC, LFTs, UEC 3-monthly; ensure TPMT checked before azathioprine
• Vaccination — annual influenza; pneumococcal; ensure live vaccines given before immunosuppression; review schedule before rituximab or high-dose steroids

Follow-up and Prevention

MCTD requires lifelong multidisciplinary follow-up. Annual PAH and ILD screening are the non-negotiable monitoring priorities. Disease evolution should be reassessed regularly with updated antibody panels and organ assessments.